Clinical Trial: NCT03800134
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2025-06-11 |
Study Overview
Brief Summary
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.
Official Title
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)
Conditions
Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: Durvalumab
- Other: Placebo
- Drug: Carboplatin
- Drug: Cisplatin
- Drug: Pemetrexed
- Drug: Paclitaxel
- Drug: Gemcitabine
- Procedure: Surgery
Other Study ID Numbers
- D9106C00001
- 2018-002997-29
- 2018
Start Date (Actual)
2018-12-06
Primary Completion Date (Actual)
2022-11-10
Study Completion Date (Estimated)
2028-09-11
Enrollment (Actual)
825
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2025-06-11 |
Study Overview
Brief Summary
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.
Official Title
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)
Conditions
Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: Durvalumab
- Other: Placebo
- Drug: Carboplatin
- Drug: Cisplatin
- Drug: Pemetrexed
- Drug: Paclitaxel
- Drug: Gemcitabine
- Procedure: Surgery
Other Study ID Numbers
- D9106C00001
- 2018-002997-29
- 2018
Start Date (Actual)
2018-12-06
Primary Completion Date (Actual)
2022-11-10
Study Completion Date (Estimated)
2028-09-11
Enrollment (Actual)
825
Study Type
Interventional
Phase
Phase 3